IP Library › Granted Patent US 9,505,737
Granted Patent B2
US 9,505,737 · App. 14/333,456 · Granted Nov 29, 2016

Treprostinil derivative compounds and methods of using same

Inventors: Cyrus K. Becker (Fremont, CA); Jürg R. Pfister (Los Altos, CA); Gwenaella Rescourio (San Mateo, CA); Meenakshi S. Venkatraman (Fremont, CA); Xiaoming Zhang (Sunnyvale, CA)
Assignee: CORSAIR PHARMA, INC.
C07D321/00A61K9/0014A61K31/165A61K31/216A61K31/341A61K31/365A61K45/06C07C59/72C07C69/712C07C69/734C07C69/74C07C69/96C07C219/16C07C235/20C07D207/08C07D211/60C07D257/06C07D263/24C07D263/26C07D265/30C07D295/088C07D295/145C07D307/20C07D317/34C07D317/40C07D453/02C07C2101/02C07C2101/08C07C2101/14C07C2102/42C07C2103/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,505,737
App. No.
14/333,456
Granted
Nov 29, 2016
Kind
B2
Abstract

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

Claims (12)

1. A compound selected from the group consisting of:

and pharmaceutically acceptable salts and solvates thereof.

2. A composition comprising a compound of claim 1 and one or more pharmaceutically acceptable carriers or excipients.

3. A method of treating pulmonary hypertension, comprising administering to a subject in need of treatment a therapeutically effective amount of a treprostinil derivative of claim 1 or a pharmaceutically acceptable salt or solvate thereof.

4. The method of claim 3 , wherein the treprostinil derivative is administered orally, topically or parenterally.

5. The method of claim 4 , wherein the treprostinil derivative is administered transdermally.

6. The method of claim 3 , wherein the pulmonary hypertension is pulmonary arterial hypertension.

7. The method of claim 3 , further comprising administering an additional therapeutic agent selected from the group consisting of vasoactive agents, diuretics, anticoagulants and cardiac glycosides.

8. The method of claim 3 , wherein:

the pulmonary hypertension is pulmonary arterial hypertension; and

the treprostinil derivative is administered transdermally.

9. The method of claim 5 , wherein the treprostinil derivative is administered via a transdermal patch.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2015
From: BECKER, CYRUS K.; PFISTER, JURG R.; RESCOURIO, GWENAELLA; VENKATRAMAN, MEENAKSHI S.; ZHANG, XIAOMING
To: CORSAIR PHARMA, INC.
Reel/Frame 034940/0927 →
Continuity (3)
Continuation In Part 14153498 · Jan 13, 2014
Provisional Application 61751608 · Jan 11, 2013
Related Publication 20150166503A1 · Jun 18, 2015